UBS

Two Chinese companies, CMBC Capital and Luye Pharma Group, are tapping the offshore loan market for the first time, seeking HK$1.4bn ($178m) and $300m respectively.

Shares in Aryzta, the frozen baked goods company listed in Ireland and Switzerland, surged by as much as 13% on Tuesday morning after it signed an agreement with five international banks to underwrite its €800m rights issue.

The World Bank is introducing a new SRI note that offers exposure to the environmental, social and governance (ESG) performance of signatories to the UN Global Compact.

Asia Cement’s first convertible bond (CB) sale in five years was priced at the best end of terms for investors, which bankers away from the deal said was “extremely cheap”.

Chinese state-owned enterprises (SOEs) Poly Real Estate Group Co and China Minmetals Corp took different approaches to pricing their dollar bonds on Monday, resulting in diverging secondary market performances.

Hua Medicine, the third biotechnology firm to list in Hong Kong, got across the finish line with an undersubscribed retail book, even though several blue-chip funds threw their weight behind the deal.

Issuers and debt bankers in Asia have their eyes fixed on the coming week for primary deal flow to gather momentum, following a relatively slow pace of issuance at the start of September.

China’s drug developer Luye Pharma Group has launched a $300m loan into general, to back the acquisition of two antipsychotic medical products.

The Asian follow-on and block markets saw two transactions in Chinese healthcare names this week that raised a total of $250m.

Qutoutiao and 111 have launched their respective IPOs on the Nasdaq this week, while Liulishuo has headed to New York for a listing.

Chinese mobile content aggregator Qutoutiao has hit the play button on its US IPO, targeting $144m from an offering of American Depository Shares (ADS).

Swiss healthcare company Roche took advantage of upcoming redemptions and a new investor base following its rating upgrade by Moody’s, to raise CHF900m ($922m) from a dual tranche offering.